Lancet has rated India's own vaccine against COVID-19, Covaxin as the one that showed enhanced immune response without showing any serious side effects.
The journal published results of the phase one trials of the Covaxin developed by Bharat Biotech in collaboration with Indian Council for Medical Research (ICMR) in its latest edition.
It said, similar peer-reviewed studies of Covaxin for the Phase 2 were still awaited and Phase 3 trials were ongoing. The government has in the meanwhile approved the vaccine for emergency use and it’s being administered along with Covishield to lakhs of frontline workers against the viral disease.
While the first two phases of vaccine trials usually focus on their safety, the third stage generally determines its efficacy.
The vaccine, codenamed BBV152, was well tolerated in all dose groups with no vaccine-related serious adverse events, noted the authors of the Lancet study funded by Bharat Biotech.
However, there has been no new data released in the public domain which could demonstrate further its safety and efficacy.
The authors said that all adverse events were mild and moderate, and were more frequent after the first dose, adding that one adverse event was reported but was unrelated to the vaccine.